blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3031920

EP3031920 - MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  19.02.2021
Database last updated on 20.11.2024
FormerThe patent has been granted
Status updated on  19.07.2019
FormerGrant of patent is intended
Status updated on  25.02.2019
FormerExamination is in progress
Status updated on  19.05.2017
FormerRequest for examination was made
Status updated on  23.12.2016
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010 / US
For all designated states
University of Rochester
601 Elmwood Avenue
Rochester, NY 14642 / US
[2016/24]
Inventor(s)01 / BENNETT, C. Frank
1896 Rutherford Road
Carlsbad, CA 92008 / US
02 / FREIER, Susan M.
1896 Rutherford Road
Carlsbad, CA 92008 / US
03 / MACLEOD, Robert A.
1896 Rutherford Road
Carlsbad, CA 92008 / US
04 / PANDEY, Sanjey K.
1896 Rutherford Road
Carlsbad, CA 92008 / US
05 / THORNTON, Charles A.
48 Palmerston Road
Rochester, NY 14618 / US
06 / WHEELER, Thurman
135 Doncaster Road
Rochester, NY 14623 / US
07 / CHENG, Seng H.
10 Jennison Circle
Natick, MA 01760 / US
08 / LEGER, Andrew
565 Massachusetts Ave
Apt. 4
Boston, MA 02118 / US
09 / WENTWORTH, Bruce M.
27 Ridge Road
Northborough, MA 01532 / US
 [2016/24]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2016/24]
Application number, filing date16153949.919.07.2011
[2016/24]
Priority number, dateUS20100365762P19.07.2010         Original published format: US 365762 P
US20100365775P19.07.2010         Original published format: US 365775 P
US201161478021P21.04.2011         Original published format: US 201161478021 P
[2016/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3031920
Date:15.06.2016
Language:EN
[2016/24]
Type: B1 Patent specification 
No.:EP3031920
Date:21.08.2019
Language:EN
[2019/34]
Search report(s)(Supplementary) European search report - dispatched on:EP11.05.2016
ClassificationIPC:C12N15/113, A61K31/7088, A61P21/00
[2016/24]
CPC:
C12N15/1137 (EP,CN,US); A61K31/7088 (KR); A61K48/00 (KR);
A61P15/00 (EP,US); A61P21/00 (EP,KR); A61P21/04 (EP);
A61P25/14 (EP); A61P25/18 (EP,US); A61P35/00 (EP,US);
A61P43/00 (EP,US); C12N15/113 (US); C12Y207/11 (EP,US);
C12N2310/11 (EP,CN,US); C12N2310/315 (EP,CN,US); C12N2310/3181 (EP,CN,US);
C12N2310/321 (CN,US); C12N2310/322 (CN); C12N2310/3231 (EP,CN,US);
C12N2310/3341 (EP,CN,US); C12N2310/341 (EP,CN,US); C12N2310/346 (EP,CN,US);
C12N2310/3525 (US) (-)
C-Set:
C12N2310/321, C12N2310/3525 (CN,EP,US);
C12N2310/321, C12N2310/3527 (US,CN,EP);
C12N2310/322, C12N2310/3533 (US,CN,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/04]
Former [2016/24]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:MODULATION DER DYSTROPHIA-MYOTONICA-PROTEINKINASE (DMPK)-EXPRESSION[2016/24]
English:MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION[2016/24]
French:MODULATION DE L'EXPRESSION D'UNE DYSTROPHIA MYOTONICA-PROTÉINE KINASE[2016/24]
Examination procedure02.02.2016Date on which the examining division has become responsible
15.12.2016Amendment by applicant (claims and/or description)
15.12.2016Examination requested  [2017/04]
18.05.2017Despatch of a communication from the examining division (Time limit: M06)
03.01.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
12.03.2018Reply to a communication from the examining division
26.04.2018Despatch of a communication from the examining division (Time limit: M06)
06.11.2018Reply to a communication from the examining division
26.02.2019Communication of intention to grant the patent
08.07.2019Fee for grant paid
08.07.2019Fee for publishing/printing paid
08.07.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP11810291.2  / EP2595663
Divisional application(s)EP19191940.6  / EP3633038
Opposition(s)Opponent(s)01  19.05.2020    ADMISSIBLE
Strawman Limited
Orchard Lea
Horns Lane
Combe, Witney
Oxfordshire OX29 8NH / GB
Opponent's representative
Teuten, Andrew John, et al, et al
Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
 [2020/26]
18.06.2020Invitation to proprietor to file observations on the notice of opposition
28.10.2020Reply of patent proprietor to notice(s) of opposition
05.11.2020Despatch of communication that the patent will be revoked
15.11.2020Legal effect of revocation of patent [2021/12]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
12.03.2018Request for further processing filed
12.03.2018Full payment received (date of receipt of payment)
Request granted
21.03.2018Decision despatched
Fees paidRenewal fee
02.02.2016Renewal fee patent year 03
02.02.2016Renewal fee patent year 04
02.02.2016Renewal fee patent year 05
11.07.2016Renewal fee patent year 06
12.07.2017Renewal fee patent year 07
11.07.2018Renewal fee patent year 08
15.07.2019Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL21.08.2019
CZ21.08.2019
EE21.08.2019
LT21.08.2019
LV21.08.2019
MC21.08.2019
MK21.08.2019
RO21.08.2019
RS21.08.2019
SI21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
LU19.07.2020
[2024/22]
Former [2021/20]AL21.08.2019
CZ21.08.2019
EE21.08.2019
LT21.08.2019
LV21.08.2019
MC21.08.2019
RO21.08.2019
RS21.08.2019
SI21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
LU19.07.2020
Former [2021/15]AL21.08.2019
CZ21.08.2019
EE21.08.2019
LT21.08.2019
LV21.08.2019
MC21.08.2019
RO21.08.2019
RS21.08.2019
SI21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/37]AL21.08.2019
CZ21.08.2019
EE21.08.2019
LT21.08.2019
LV21.08.2019
RO21.08.2019
RS21.08.2019
SI21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/36]AL21.08.2019
CZ21.08.2019
EE21.08.2019
LT21.08.2019
LV21.08.2019
RO21.08.2019
RS21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/27]AL21.08.2019
CZ21.08.2019
EE21.08.2019
LT21.08.2019
LV21.08.2019
RO21.08.2019
RS21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
PT23.12.2019
IS24.02.2020
Former [2020/26]AL21.08.2019
CZ21.08.2019
EE21.08.2019
LT21.08.2019
LV21.08.2019
RO21.08.2019
RS21.08.2019
SK21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
PT23.12.2019
IS24.02.2020
Former [2020/24]AL21.08.2019
EE21.08.2019
LT21.08.2019
LV21.08.2019
RO21.08.2019
RS21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
PT23.12.2019
IS24.02.2020
Former [2020/23]AL21.08.2019
EE21.08.2019
LT21.08.2019
LV21.08.2019
RO21.08.2019
RS21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/22]AL21.08.2019
EE21.08.2019
LT21.08.2019
LV21.08.2019
RS21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/17]AL21.08.2019
LT21.08.2019
LV21.08.2019
RS21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/15]AL21.08.2019
LT21.08.2019
LV21.08.2019
RS21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/12]LT21.08.2019
LV21.08.2019
RS21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/10]LT21.08.2019
BG21.11.2019
PT23.12.2019
Former [2020/08]LT21.08.2019
Documents cited:Search[XI]WO2008018795  (PROSENSA BV [NL], et al) [X] 1-8,10,14,15 * the whole document * [I] 1-15;
 [XDI]WO2008036406  (UNIV ROCHESTER [US], et al) [XD] 1-7,15 * the whole document * [I] 1-15;
 [XI]US2010016215  (MOULTON HONG M [US], et al) [X] 1-7,14,15 * the whole document * [I] 1-15;
 [XPI]WO2010115993  (ASS I DE MYOLOGIE [FR], et al) [XP] 1-6,10,15 * page 8 - page 10; figures 20, 21; examples 9, 10; claims 45-65; sequences 7-9 * [I] 7-9,11-14;
 [E]WO2011097641  (ISIS PHARMACEUTICALS INC [US], et al) [E] 1-15 * page 1 - page 3 * * page 34, line 20 - page 35, line 10 ** example 15; claims 38-70 *;
 [XI]  - S. A. M. MULDERS ET AL, "Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20090818), vol. 106, no. 33, doi:10.1073/pnas.0905780106, ISSN 0027-8424, pages 13915 - 13920, XP055007026 [X] 1,3-8,10,15 * the whole document * [I] 1-15

DOI:   http://dx.doi.org/10.1073/pnas.0905780106
 [XDI]  - T. M. WHEELER ET AL, "Reversal of RNA Dominance by Displacement of Protein Sequestered on Triplet Repeat RNA", SCIENCE, (20090717), vol. 325, no. 5938, doi:10.1126/science.1173110, ISSN 0036-8075, pages 336 - 339, XP055012134 [XD] 1,3-7,15 * the whole document * [I] 1-15

DOI:   http://dx.doi.org/10.1126/science.1173110
 [I]  - Lee, JE and Cooper TA, "TARGETED DEGRADATION OF TOXIC RNA IN MYOTONICDYSTROPHY", Lee, JE and Cooper TA, Kole, R and Krainer, AR and Sullenger, B, Abstracts of papers presented at the 2010 meeting on RNA & oligonucleotide therapeutics, April 7-10, 2010, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, (20100318), pages 35 - 35, ISBN 9789990251784, XP002718910 [I] 1-15 * the whole document *
Examination   - CHO ET AL, "Myotonic dystrophy: Emerging mechanisms for DM1 and DM2", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE, AMSTERDAM, NL, (20070123), vol. 1772, no. 2, doi:10.1016/J.BBADIS.2006.05.013, ISSN 0925-4439, pages 195 - 204, XP005856205

DOI:   http://dx.doi.org/10.1016/j.bbadis.2006.05.013
    - ANNEMIEKE AARTSMA-RUS ET AL, "Progress in therapeutic antisense applications for neuromuscular disorders", EUROPEAN JOURNAL OF HUMAN GENETICS, (20100201), vol. 18, no. 2, doi:10.1038/ejhg.2009.160, ISSN 1018-4813, pages 146 - 153, XP055035165

DOI:   http://dx.doi.org/10.1038/ejhg.2009.160
    - JAUVIN DOMINIC ET AL, "Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice", MOLECULAR THERAPY-NUCLEIC ACIDS, (20170616), vol. 7, pages 465 - 474
by applicantWO9414226
 WO9839352
 WO9914226
 US6268490
 WO03004602
 US6525191
 US6670461
 US6770748
 US2004171570
 US6794499
 WO2004106356
 WO2005021570
 US2005130923
 US7034133
 US7053207
 WO2007134181
 US2007287831
 US2008039618
 WO2008036406
 US7399845
 WO2008101157
 US7427672
 WO2008150729
 WO2008154401
 WO2009006478
 WO2010036696
    - BROOK JD ET AL., CELL, (1992), vol. 68, no. 4, pages 799 - 808
    - OSBOME RJ; THORNTON CA., HUMAN MOLECULAR GENETICS., (2006), vol. 15, no. 2, pages R162 - R169
    - ANNU. REV. NEUROSCI., (2006), vol. 29, page 259
    - EMBO J., (2000), vol. 19, page 4439
    - CURR OPIN NEUROL., (2007), vol. 20, page 572
    - WHEELER TM ET AL., SCIENCE, (2009), vol. 325, no. 5938, pages 336 - 339
    - MULDERS SA ET AL., PROC NATL ACAD SCI USA., (2009), vol. 106, no. 33, pages 13915 - 13920
    - DE DIE-SMULDERS CE ET AL., BRAIN, (1998), vol. 121, pages 1557 - 1563
    - WOOLF ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, pages 7305 - 7309
    - GAUTSCHI ET AL., J. NATL. CANCER INST., (200103), vol. 93, pages 463 - 471
    - MAHER; DOLNICK, NUC. ACID. RES., (1988), vol. 16, pages 3341 - 3358
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
    - ZHANG; MADDEN, GENOME RES., (1997), vol. 7, pages 649 - 656
    - SMITH; WATERMAN, ADV. APPL. MATH., (1981), vol. 2, pages 482 - 489
    - CHATTOPADHYAYA ET AL., J ORG. CHEM., (2009), vol. 74, pages 118 - 134
    - SRIVASTAVA ET AL., J. AM. CHEM. SOC., (2007), vol. 129, no. 26, pages 8362 - 8379
    - FRIEDEN ET AL., NUCLEIC ACIDS RESEARCH, (2003), vol. 21, pages 6365 - 6372
    - ELAYADI ET AL., CURR. OPINION INVENS. DRUGS, (2001), vol. 2, pages 558 - 561
    - ORUM ET AL., CURR. OPINION MOL. THER., (2001), vol. 3, pages 239 - 243
    - WAHLESTEDT ET AL., PROC. NATL. ACAD SCI. U. S. A., (2000), vol. 97, pages 5633 - 5638
    - SINGH ET AL., CHEM. COMMUN., (1998), vol. 4, pages 455 - 456
    - KOSHKIN ET AL., TETRAHEDRON, (1998), vol. 54, pages 3607 - 3630
    - KUMAR ET AL., BIOORG. MED. CHEM. LETT., (1998), vol. 8, pages 2219 - 2222
    - SINGH ET AL., J. ORG. CHEM., (1998), vol. 63, pages 10035 - 10039
    - SINGH ET AL., J ORG. CHEM., (1998), vol. 63, pages 10035 - 10039
    - FRIER ET AL., NUCLEIC ACIDS RESEARCH, (1997), vol. 25, no. 22, pages 4429 - 4443
    - ALBAEK ET AL., J. ORG. CHEM., (2006), vol. 71, pages 7731 - 7740
    - LEUMANN, C. J., BIOORG. & MED. CHEM., (2002), vol. 10, pages 841 - 854
    - ROBEYNS ET AL., J. AM. CHEM. SOC., (2008), vol. 130, no. 6, pages 1979 - 1984
    - HORVÁTH ET AL., TETRAHEDRON LETTERS, (2007), vol. 48, pages 3621 - 3623
    - NAUWELAERTS ET AL., J. AM. CHEM. SOC., (2007), vol. 129, no. 30, pages 9340 - 9348
    - GU ET AL., NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, (2005), vol. 24, no. 5-7, pages 993 - 998
    - NAUWELAERTS ET AL., NUCLEIC ACIDS RESEARCH, (2005), vol. 33, no. 8, pages 2452 - 2463
    - ROBEYNS ET AL., ACTA CRYSTALLOGRAPHICA, SECTION F: STRUCTURAL BIOLOGY AND CRYSTALLIZATION COMMUNICATIONS, (2005), vol. F61, no. 6, pages 585 - 586
    - GU ET AL., TETRAHEDRON, (2004), vol. 60, no. 9, pages 2111 - 2123
    - GU ET AL., OLIGONUCLEOTIDES, (2003), vol. 13, no. 6, pages 479 - 489
    - WANG ET AL., J. ORG. CHEM., (2003), vol. 68, pages 4499 - 4505
    - VERBEURE ET AL., NUCLEIC ACIDS RESEARCH, (2001), vol. 29, no. 24, pages 4941 - 4947
    - WANG ET AL., J. ORG. CHEM., (2001), vol. 66, pages 8478 - 82
    - WANG ET AL., NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, (2001), vol. 20, no. 4-7, pages 785 - 788
    - WANG ET AL., J. AM. CHEM., (2000), vol. 122, pages 8595 - 8602
    - Antisense Research and Applications, CRC PRESS, (1993), pages 276 - 278
    - JONES, L.J. ET AL., ANALYTICAL BIOCHEMISTRY, (1998), vol. 265, pages 368 - 374
    - MANKODI, A ET AL., SCIENCE, (2000), vol. 289, page 1769
    - MANKODI, A. ET AL., MOL. CELL, (2002), vol. 10, page 35
    - LIN, X. ET AL., HUM. MOL. GENET., (2006), vol. 15, page 2087
    - BROOK, J.D ET AL., CELL, (1992), vol. 68, page 799
    - DAVIS, B.M ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1997), vol. 94, page 7388
    - MILLER, J.W. ET AL., EMBO J., (2000), vol. 19, page 4439
    - DAVIS ET AL., PROC. NATL. ACAD SCI. U. S. A, (1997), vol. 94, pages 7388 - 7393
    - MANKODI, A. ET AL., SCIENCE, (2000), vol. 289, page 1769
    - MANKODI, A ET AL., MOL. CELL, (2002), vol. 10, page 35
    - LIN, X ET AL., HUM. MOL. GENET., (2006), vol. 15, page 2087
    - KANADIA ET AL., SCIENCE, (2003), vol. 302, pages 1978 - 1980
    - BENNETT; SWAYZE, ANNU. REV. PHARMACOL., (2010), vol. 50, pages 259 - 93
    - BUTLER ET AL., DIABETES, (2002), vol. 51, pages 1028 - 34
    - LEVIN ET AL., Antisense Drug Technology: Principles, Strategies, and Applications, CRC PRESS, (2008), pages 183 - 215
    - GEARY ET AL., DRUG METAB. DISPOS, (2003), vol. 31, pages 1419 - 28
 US20080097787
 US20080086231
 US20080026995
 US20070989574
 US20080026998
 US20080056564
 US20080129154
 US20080099844
OppositionWO2008018795
 WO2015021457
    - S. A. M. Mulders et al, "Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20090818), vol. 106, no. 33, doi:10.1073/pnas.0905780106, ISSN 0027-8424, pages 13915 - 13920, XP055007026

DOI:   http://dx.doi.org/10.1073/pnas.0905780106
    - M.-A. Langlois, C. Boniface, G. Wang, J. Alluin, P. M. Salvaterra, J. Puymirat, J. J. Rossi, N. S. Lee, "Cytoplasmic and Nuclear Retained DMPK mRNAs Are Targets for RNA Interference in Myotonic Dystrophy Cells", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, (20050429), vol. 280, no. 17, doi:10.1074/jbc.M501591200, ISSN 00219258, pages 16949 - 16954, XP055147962

DOI:   http://dx.doi.org/10.1074/jbc.M501591200
    - LANGLOIS MARC-ANDRE ET AL, "Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts.", Molecular therapy, Cell Press, US, US, (20030501), vol. 7, no. 5 Pt 1, doi:10.1016/S1525-0016(03)00068-6, ISSN 1525-0016, pages 670 - 680, XP002423926

DOI:   http://dx.doi.org/10.1016/S1525-0016(03)00068-6
    - C. Frank Bennett, Eric E. Swayze, "RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform", Annual Review of Pharmacology and Toxicology, Annual Reviews Inc., (20100201), vol. 50, no. 1, doi:10.1146/annurev.pharmtox.010909.105654, ISSN 03621642, pages 259 - 293, XP055055378

DOI:   http://dx.doi.org/10.1146/annurev.pharmtox.010909.105654
    - Elif Sarinay Cenik; Phillip D. Zamore;, "Argonaute proteins", CURRENT BIOLOGY, CURRENT SCIENCE, GB, GB, vol. 21, no. 12, doi:10.1016/j.cub.2011.05.020, ISSN 0960-9822, pages R446 - R449, XP028230700

DOI:   http://dx.doi.org/10.1016/j.cub.2011.05.020
    - Keith t. Gagnon, Liande Li, Yongjun Chu, Bethany a. Janowski, David r. Corey, "RNAi Factors Are Present and Active in Human Cell Nuclei", Cell Reports, Elsevier Inc., US, US, (20140101), vol. 6, no. 1, doi:10.1016/j.celrep.2013.12.013, ISSN 2211-1247, pages 211 - 221, XP055742100

DOI:   http://dx.doi.org/10.1016/j.celrep.2013.12.013
    - Michaela Scherr, Et Al, "Detection of Antisense and Ribozyme Accessible Sites on Native mRNAs: Application to NCOA3 mRNA", Molecular therapy, Cell Press, US, US, (20011101), vol. 4, no. 5, doi:10.1006/mthe.2001.0481, ISSN 1525-0016, pages 454 - 460, XP055742103

DOI:   http://dx.doi.org/10.1006/mthe.2001.0481
    - Kevin Scanlon, "Anti-Genes: siRNA, Ribozymes and Antisense", CURRENT PHARMACEUTICAL BIOTECHNOLOGY, BENTHAM SCIENCE PUBLISHERS,, NL, NL, (20041001), vol. 5, no. 5, doi:10.2174/1389201043376689, ISSN 1389-2010, pages 415 - 420, XP055742104

DOI:   http://dx.doi.org/10.2174/1389201043376689
    - KURRECK J, "ANTISENSE TECHNOLOGIES IMPROVEMENT THROUGH NOVEL CHEMICAL MODIFICATIONS", European Journal of Biochemistry, Wiley-Blackwell Publishing Ltd., GB, GB, (20030401), vol. 270, no. 08, doi:10.1046/j.1432-1033.2003.03555.x, ISSN 0014-2956, pages 1628 - 1644, XP009045309

DOI:   http://dx.doi.org/10.1046/j.1432-1033.2003.03555.x
    - MONIA B. P., ET AL., "EVALUATION OF 2'-MODIFIED OLIGONUCLEOTIDES CONTAINING 2'-DEOXY GAPSAS ANTISENSE INHIBITORS OF GENE EXPRESSION.", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US, (19930705), vol. 268., no. 19., ISSN 0021-9258, pages 14514 - 14522., XP000576145
    - Dominic Jauvin, Et Al, "Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice", MOLECULAR THERAPY-NUCLEIC ACIDS, Cell Press, US, US, (20170601), vol. 7, doi:10.1016/j.omtn.2017.05.007, ISSN 2162-2531, pages 465 - 474, XP055742109

DOI:   http://dx.doi.org/10.1016/j.omtn.2017.05.007
    - Marc-Andre Langlois, Et Al, "Ribozyme and Anitisense RNA-Based Gene Therapies for Myotonic Dystrophy", Molecular Therapy, (20030501), vol. 7, no. 5, page S320, XP055742113
    - Gilles Doucet, "RNA-Based gene therapy for myotonic dystrophy type 1 (DM1)", THE OTTAWA CONFERENCE ON NEW DIRECTIONS IN BIOLOGY & DISEASE OF SKELETAL MUSCLE, (20100805), page 67, XP055742116
    - Xue-Hai Liang, Hong Sun, Joshua G. Nichols, Stanley T. Crooke, "RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus", Molecular therapy, Cell Press, US, US, (20170901), vol. 25, no. 9, doi:10.1016/j.ymthe.2017.06.002, ISSN 1525-0016, pages 2075 - 2092, XP055575667

DOI:   http://dx.doi.org/10.1016/j.ymthe.2017.06.002
    - Misha Koshelev, Et Al, "Therapeutic application for a cell culture model of myotonic dystrophy", New Directions in Biology & Disease of Skeletal Muscle 2008, (20080427), page 44, XP055742119
    - VICKERS T A,ET AL, "Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents: A comparative analysis.", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US, (20030228), vol. 278, no. 9, doi:10.1074/jbc.M210326200, ISSN 0021-9258, pages 7108 - 7118, XP002281434

DOI:   http://dx.doi.org/10.1074/jbc.M210326200
    - MULDERS et al., 7th International Myotonic Dystrophy Consortium Meeting (IDMC-7, Würzburg, Germany, (20090909), pages 1 - 57
    - Conference program 2010 meeting of RNA & Oligonucleotide Therapeutics, New York USA, (20100410), pages 1 - 54
    - FURLING D, ET AL., "Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions", Gene Therapy, Nature Publishing Group, London, GB, GB, (20030501), vol. 10, no. 9, doi:10.1038/sj.gt.3301955, ISSN 0969-7128, pages 795 - 802, XP002484831

DOI:   http://dx.doi.org/10.1038/sj.gt.3301955
    - D Furling, Et Al, "Therapeutic rna strategies for myotonic dystrophy with ctg repeats", Abstracts Neuromuscular Disorders, (20040101), vol. 14, page 585, XP055742130
    - U. Galderisi, M. et al, "Myotonic Dystrophy: Antisense Oligonucleotide Inhibition of DMPK Gene Expression in Vitro", Biochemical and Biophysical Research Communications, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL, (19960101), vol. 221, ISSN 0006-291X, pages 750 - 754, XP007911722

DOI:   http://dx.doi.org/10.1006/bbrc.1996.0668
    - S. A. M. Mulders, Van Engelen B. G. M., Wieringa B., Wansink D. G., "Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function", Human Molecular Genetics, (20100415), vol. 19, no. R1, doi:10.1093/hmg/ddq161, ISSN 09646906, pages R90 - R97, XP055007054

DOI:   http://dx.doi.org/10.1093/hmg/ddq161
    - Graphs showing percentage inhibition vs target site for gapmers from Tables 1, 3, 12 and 13
    - Wheeler, T.M., "Myotonic Dystrophy: Therapeutic Strategies for the Future", Neurotherapeutics, ELSEVIER INC., US, US, (20081001), vol. 5, no. 4, doi:10.1016/j.nurt.2008.08.001, ISSN 1933-7213, pages 592 - 600, XP025480971

DOI:   http://dx.doi.org/10.1016/j.nurt.2008.08.001
    - STEIN C.A. ET AL, "The experimental use of antisense oligonucleotides: a guide for the pe", The Journal of Clinical Investigation, B M J Group, GB, GB, (20010901), vol. 108, no. 5, doi:10.1172/JCI200113885, ISSN 0021-9738, pages 641 - 644, XP002986037

DOI:   http://dx.doi.org/10.1172/JCI200113885
    - T. M. Wheeler, K. Sobczak, J. D. Lueck, R. J. Osborne, X. Lin, R. T. Dirksen, C. A. Thornton, "Reversal of RNA Dominance by Displacement of Protein Sequestered on Triplet Repeat RNA", Science, American Association for the Advancement of Science, (20090717), vol. 325, no. 5938, doi:10.1126/science.1173110, ISSN 00368075, pages 336 - 339, XP055012134

DOI:   http://dx.doi.org/10.1126/science.1173110
    - Cho, D.H. Tapscott, S.J., "Myotonic dystrophy: Emerging mechanisms for DM1 and DM2", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE., AMSTERDAM, NL, NL, (20070123), vol. 1772, no. 2, doi:10.1016/j.bbadis.2006.05.013, ISSN 0925-4439, pages 195 - 204, XP005856205

DOI:   http://dx.doi.org/10.1016/j.bbadis.2006.05.013
    - Anonymous, "Baliforsen - Ionis Pharmaceuticals - AdisInsight", Adis Insight, (20161115), pages 1 - 9, XP055742135
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.